Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial.

Date publication

août 2025

Journal

Lancet (London, England)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr VERNEREY Dewi , Mme HENRIQUES Julie

Tous les auteurs :
Brain E, Mir O, Bourbouloux E, Rigal O, Ferrero JM, Kirscher S, Allouache D, D'Hondt V, Savoye AM, Durando X, Duhoux FP, Venat-Bouvet L, Blot E, Canon JL, Rollot-Trad F, Bonnefoi H, Roque T, Lemonnier J, Latouche A, Henriques J, Lacroix-Triki M, Vernerey D,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40752909

Résumé

For women aged 70 years or older with oestrogen receptor-positive HER2-negative invasive breast cancer, hormonotherapy is a standard adjuvant treatment, while the role of chemotherapy is debated. We aimed to assess the effect of adjuvant chemotherapy on overall survival in these older patients with high-risk tumours according to a prognostic genomic signature.

Mots clés

Humans, Female, Breast Neoplasms, genetics, Chemotherapy, Adjuvant, Aged, Aged, 80 and over, Antineoplastic Agents, Hormonal, therapeutic use, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Neoplasm Grading, France

Référence

Lancet. 2025 08 2;406(10502):489-500